Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections.

Inhaled antibiotics significantly impact respiratory-disorder management through targeted delivery with reduced systemic side effects. Advances in pharmaceutical formulations, particularly lipid-based nanomedicine, help improve biopharmaceutical performance and therapeutic efficacy. In addition, advancements in inhaler technologies ensure effective lung deposition and minimize systemic exposure. These innovations have further benefited chronic respiratory diseases like cystic fibrosis and COPD, where infections are frequent. For instance, the encapsulation of inhaled antibiotics, particularly the tobramycin liposomal system, has improved efficacy and reduced toxicity, whereas the nebulized colistin nanoformulation effectively targets multidrug-resistant pathogens, including the clinical efficacy of amikacin liposome inhalation in refractory pulmonary infections. Overall, advancements in lipid-based nanoformulation and delivery technologies have significantly enhanced the utility of inhaled antibiotics, providing safer and more-effective options for managing chronic and resistant infections.